Sangamo Q4 2020 Earnings Report
Key Takeaways
Sangamo Therapeutics reported a consolidated net loss of $40.7 million for the fourth quarter ended December 31, 2020, compared to net income of $4.5 million for the same period in 2019. Revenues for the fourth quarter ended December 31, 2020 were $25.8 million, compared to $54.9 million for the same period in 2019. Cash, cash equivalents and marketable securities as of December 31, 2020 were $692.0 million, compared to $384.3 million as of December 31, 2019.
Presented updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec with Pfizer, demonstrating sustained Factor VIII activity levels.
Announced the first participant has been dosed in the registrational Phase 3 AFFINE trial of giroctocogene fitelparvovec with Pfizer.
Completed dosing of the third patient in the Phase 1/2 STAAR study evaluating ST-920 gene therapy for Fabry disease.
Brought in-house AAV manufacturing capabilities online in Sangamo’s Brisbane, California headquarters.
Sangamo
Sangamo
Forward Guidance
On a GAAP basis, we expect total operating expenses in the range of approximately $285 million to $305 million in 2021, which includes non-cash stock-based compensation expense. We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $30 million, in the range of approximately $255 million to $275 million.